Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.56 | N/A | +147.26% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.56 | N/A | +147.26% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings surprise, highlighting their commitment to pipeline advancements. They emphasized the importance of maintaining operational efficiency.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and delivering value.
Alnylam Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations, which led to a notable stock increase of 13.12%. The positive EPS surprise reflects effective cost management and operational performance. However, the lack of revenue data and guidance leaves some uncertainty about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ON SEMICONDUCTOR COR
Jul 29, 2024